These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 23960879)

  • 1. Role of Avastin in management of central serous chorioretinopathy.
    Mehany SA; Shawkat AM; Sayed MF; Mourad KM
    Saudi J Ophthalmol; 2010 Jul; 24(3):69-75. PubMed ID: 23960879
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Early Avastin management in acute retinal vein occlusion.
    Mehany SA; Mourad KM; Shawkat AM; Sayed MF
    Saudi J Ophthalmol; 2010 Jul; 24(3):87-94. PubMed ID: 23960882
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intravitreal bevacizumab to treat acute central serous chorioretinopathy: short-term effect.
    Seong HK; Bae JH; Kim ES; Han JR; Nam WH; Kim HK
    Ophthalmologica; 2009; 223(5):343-7. PubMed ID: 19521133
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intravitreal bevacizumab for treatment of chronic central serous chorioretinopathy.
    Schaal KB; Hoeh AE; Scheuerle A; Schuett F; Dithmar S
    Eur J Ophthalmol; 2009; 19(4):613-7. PubMed ID: 19551677
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Half-Fluence Photodynamic Therapy for Chronic Central Serous Chorioretinopathy: Predisposing Factors for Visual Acuity Outcomes.
    Matušková V; Vysloužilová D; Uher M
    Semin Ophthalmol; 2018; 33(5):690-699. PubMed ID: 29252091
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Selective retina therapy (SRT) in patients with therapy refractory persistent acute central serous chorioretinopathy (CSC): 3 months functional and morphological results.
    Büttner M; Luger B; Abou Moulig W; Junker B; Framme C; Jacobsen C; Knoll K; Pielen A;
    Graefes Arch Clin Exp Ophthalmol; 2021 Jun; 259(6):1401-1410. PubMed ID: 33205239
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The efficacy of intravitreal bevacizumab for acute central serous chorioretinopathy.
    Aydin E
    J Ocul Pharmacol Ther; 2013 Feb; 29(1):10-3. PubMed ID: 22925113
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intravitreal bevacizumab (avastin) for choroidal neovascularization secondary to central serous chorioretinopathy, secondary to punctate inner choroidopathy, or of idiopathic origin.
    Chan WM; Lai TY; Liu DT; Lam DS
    Am J Ophthalmol; 2007 Jun; 143(6):977-983. PubMed ID: 17459318
    [TBL] [Abstract][Full Text] [Related]  

  • 9. TWELVE-MONTH EFFICACY OF INTRAVITREAL BEVACIZUMAB INJECTION FOR CHRONIC, ATYPICAL, OR RECURRENT CENTRAL SEROUS CHORIORETINOPATHY.
    Chung YR; Kim JW; Song JH; Park A; Kim MH
    Retina; 2019 Jan; 39(1):134-142. PubMed ID: 29077604
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intravitreal Bevacizumab for Treatment of Central Serous Chorioretinopathy.
    Ünlü C; Erdogan G; Aydogan T; Sezgin Akcay BI; Kardes E; Kiray GA; Bozkurt TK
    J Ophthalmic Vis Res; 2016; 11(1):61-5. PubMed ID: 27195087
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anatomical and visual outcome of intravitreal bevacizumab (Avastin) in patients with diabetic macular edema.
    Vyas S; Thapa R; Bajimaya S; Pradhan E; Paudyal G
    Nepal J Ophthalmol; 2016 Jan; 8(15):54-61. PubMed ID: 28242886
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Primary intravitreal bevacizumab (Avastin) for diabetic macular edema: results from the Pan-American Collaborative Retina Study Group at 6-month follow-up.
    Arevalo JF; Fromow-Guerra J; Quiroz-Mercado H; Sanchez JG; Wu L; Maia M; Berrocal MH; Solis-Vivanco A; Farah ME;
    Ophthalmology; 2007 Apr; 114(4):743-50. PubMed ID: 17398322
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intravitreal ranibizumab in the treatment of choroidal neovascularization associated with idiopathic central serous chorioretinopathy.
    Konstantinidis L; Mantel I; Zografos L; Ambresin A
    Eur J Ophthalmol; 2010; 20(5):955-8. PubMed ID: 20306440
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Observation on long-term efficacy of half-dose photodynamic therapy with chronic central serous chorioretinopathy using optical coherence tomography].
    Liu Y; Li L; Xu G; Wang W
    Zhonghua Yan Ke Za Zhi; 2016 May; 52(5):328-34. PubMed ID: 27220704
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Low-fluence photodynamic therapy versus ranibizumab for chronic central serous chorioretinopathy: one-year results of a randomized trial.
    Bae SH; Heo J; Kim C; Kim TW; Shin JY; Lee JY; Song SJ; Park TK; Moon SW; Chung H
    Ophthalmology; 2014 Feb; 121(2):558-65. PubMed ID: 24268858
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Visual and Anatomical Outcomes of Spironolactone Therapy in Patients with Chronic Central Serous Chorioretinopathy.
    Falavarjani KG; Amirsardari A; Habibi A; Eshaghi A; Bakhti S; Aghdam KA
    J Ophthalmic Vis Res; 2017; 12(3):281-289. PubMed ID: 28791061
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Single-session combined photodynamic therapy with verteporfin and intravitreal anti-vascular endothelial growth factor therapy for chronic central serous chorioretinopathy: a pilot study at 12-month follow-up.
    Arevalo JF; Espinoza JV
    Graefes Arch Clin Exp Ophthalmol; 2011 Aug; 249(8):1159-66. PubMed ID: 21448811
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical evaluation of neovascular and non-neovascular chronic central serous chorioretinopathy (CSC) diagnosed by swept source optical coherence tomography angiography (SS OCTA).
    Sulzbacher F; Schütze C; Burgmüller M; Vécsei-Marlovits PV; Weingessel B
    Graefes Arch Clin Exp Ophthalmol; 2019 Aug; 257(8):1581-1590. PubMed ID: 31037488
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intravitreal bevacizumab (Avastin) therapy for persistent diffuse diabetic macular edema.
    Haritoglou C; Kook D; Neubauer A; Wolf A; Priglinger S; Strauss R; Gandorfer A; Ulbig M; Kampik A
    Retina; 2006; 26(9):999-1005. PubMed ID: 17151486
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The efficacy of intravitreal bevacizumab for idiopathic central serous chorioretinopathy.
    Lim JW; Kim MU
    Graefes Arch Clin Exp Ophthalmol; 2011 Jul; 249(7):969-74. PubMed ID: 21140161
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.